Clinical Trials Browser

Withdrawn × INDUSTRY × sintilimab × Clear all

NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Phase 1/2 Withdrawn

Melanoma, Neoplasms